Eli Lilly and Co (XSWX:LLY) PE Ratio: 42.54 (As of Jun. 27, 2026) — Near Median


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF955.00
GF Value CHF1,114.27
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co PE Ratio?

Eli Lilly and Co XSWX:LLY +4.37% 100 PE Ratio is 42.54 as of Jun. 27, 2026, which is 3% above its 10-year median of 41.36. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,114.27 (Modestly Undervalued). The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-27), Eli Lilly and Co's share price is CHF955.00. Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF22.45. Therefore, Eli Lilly and Co's PE Ratio for today is 42.54.

During the past 13 years, Eli Lilly and Co's highest PE Ratio was 263.64. The lowest was 13.22. And the median was 41.36.

Eli Lilly and Co's EPS (Diluted) for the three months ended in Mar. 2026 was CHF6.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF22.45.

As of today (2026-06-27), Eli Lilly and Co's share price is CHF955.00. Eli Lilly and Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was CHF23.47. Therefore, Eli Lilly and Co's PE Ratio without NRI ratio for today is 40.68.

During the past 13 years, Eli Lilly and Co's highest PE Ratio without NRI was 124.37. The lowest was 17.25. And the median was 28.79.

Eli Lilly and Co's EPS without NRI for the three months ended in Mar. 2026 was CHF6.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was CHF23.47.

During the past 12 months, Eli Lilly and Co's average EPS without NRI Growth Rate was 113.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 45.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.20% per year.

During the past 13 years, Eli Lilly and Co's highest 3-Year average EPS without NRI Growth Rate was 49.00% per year. The lowest was -27.40% per year. And the median was 12.30% per year.

Eli Lilly and Co's EPS (Basic) for the three months ended in Mar. 2026 was CHF6.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF22.50.

Back to Basics: PE Ratio


Eli Lilly and Co  (XSWX:LLY) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Eli Lilly and Co PE Ratio Related Terms


Eli Lilly and Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co PE Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.13 53.02 100.50 65.93 46.83

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.20 50.95 37.33 46.83 32.67

XSWX:LLY vs JNJ, ABBV, MRK: PE Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's PE Ratio falls into.


XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Eli Lilly and Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=955.00/22.451
=42.54

Eli Lilly and Co's Share Price of today is CHF955.00.
Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF22.45.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 42.54 mean?
Eli Lilly and Co (XSWX:LLY) has a PE Ratio of 42.54 as of Jun. 27, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Eli Lilly and Co and its competitors. This is near median its historical median of 41.36. Over the past decade, Eli Lilly and Co's PE Ratio has ranged from 13.22 to 263.64.
Is Eli Lilly and Co's PE Ratio too high?
Eli Lilly and Co's current PE Ratio of 42.54 is near median its 10-year median of 41.36. Over the past 10 years, this metric has ranged from a low of 13.22 to a high of 263.64. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's PE Ratio compare to JNJ and ABBV?
Eli Lilly and Co's PE Ratio of 42.54 can be compared against companies in the Drug Manufacturers industry. Historically, Eli Lilly and Co's own PE Ratio has ranged from 13.22 to 263.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current PE Ratio is 42.54, which is near median its own 10-year median of 41.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,114.27, compared to a current price of CHF955.00 — trading 14.3% below its estimated fair value. The current PE Ratio is 42.54, which is near median its 10-year median of 41.36. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current PE Ratio is 42.54 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF955.00 is trading 14.3% below its estimated GF Value™ of CHF1,114.27. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • PE Ratio: 42.54 (near median its 10-year median of 41.36)
  • GF Value™: CHF1,114.27 vs. price of CHF955.00 (14.3% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF955.00
Price
CHF1,114.27
GF Value